Program Schedule

4
Clostridium difficile Treatment - State of the Art

Wednesday, October 8, 2014: 1:30 PM-3:30 PM
Room: The Pennsylvania Convention Center: 118-ABC
IDSA Clinical Affairs Committee

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe current diagnostic techniques for diagnosing C. difficile
  • employ the use of fecal microbiota transplantation in controlling C. difficile

Target Audience: Scientists, Researchers, Pharmacists, Nurses, Microbiologists, Members-in-training, Lab personnel, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Hospital administrators, Health care workers, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Epidemiology and Infection Control, Adult ID

Moderators:  Daniel McQuillen, MD, FIDSA, Lahey Hospital & Medical Center and Thomas Moore, MD, FIDSA, University of Kansas School of Medicine-Wichita Campus

Presentations:
1:30 PM
12
Current Diagnostics and When and How to Use Them
L. Clifford Mcdonald, MD, FACP, FSHEA
2:00 PM
13
2:30 PM
14
Fecal Microbiota Transplantation
Colleen R. Kelly, MD
3:00 PM
15
Challenging Cases
Mcdonald, Peto, Kelly, and Moore

CME Credits: Maximum of 2 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-092-L01-P

Disclosures:

D. McQuillen, None

T. Moore, None

L. C. Mcdonald, None

T. Peto, optimer: Scientific Advisor, Consulting fee

C. R. Kelly, USendoscopy: Consultant, Consulting fee
Seres Health: site investigator, No personal financial benefit; budget with my institution to do the research
Fecal Transplant Foundation: scientific advisory board, no financial benefit

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek